Introduction: The recent global pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has involved more than 7 million people worldwide and been associated with more than 400,000 deaths. No clear information is known about all the potential risk factors for COVID-19 or what factors adversely influence its clinical course and mortality. Therefore, we analyzed the role of obesity, type 2 diabetes, and hypertension as risk factors for COVID-19. Methods: We identified articles for inclusion by searching PubMed and Google Scholar (last accessed 15 June 2020). Retrospective review of literature. Analysis of epidemiological data concerning obesity prevalence and COVID-19 incidence, particularly in Italy and the USA. Results: Data from several retrospective studies of prevalence showed that patients with hypertension, type 2 diabetes, and obesity may have more severe COVID-19, intensive care unit admission, and higher mortality rates, but it is not definitively clear if this is an independent association. In general, the prevalence of obesity in patients with COVID-19 seems to bethe same as that of the general population throughout the world; however, obesity seems to be associated with more severe disease and mortality in younger (< 60 years) patients. Similar effects seem to occur in patients with diabetes and/or hypertension but at older ages (> 60 years). In strict connection, it has been proposed that the use of drugs inhibiting angiotensin-converting enzyme 2 (ACE-2) or dipeptidyl dipeptidase 4 (DPP-4) might influence viral activity and disease severity since ACE-2 and DPP-4 receptors mediate SARS-CoV- 2 entry into the host cells; however, no evidence exists to date that shows that this may be the case. Conclusion: Overall, diabetes, hypertension, and obesity seem to negatively affect the clinical course and disease outcome in patients with COVID-19. However, these data need further confirmation by studies with more accurate data registration.

Buscemi, S., Corleo, D., Randazzo, C. (2022). Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity. In A. Asea, P. Kaur (a cura di), Coronavirus Therapeutics, Advances in Experimental Medicine and Biology (pp. 115-129). Springer Nature [10.1007/978-3-030-85113-2_7].

Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity

Buscemi, Silvio
Primo
;
Corleo, Davide;Randazzo, Cristiana
Ultimo
2022-01-01

Abstract

Introduction: The recent global pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has involved more than 7 million people worldwide and been associated with more than 400,000 deaths. No clear information is known about all the potential risk factors for COVID-19 or what factors adversely influence its clinical course and mortality. Therefore, we analyzed the role of obesity, type 2 diabetes, and hypertension as risk factors for COVID-19. Methods: We identified articles for inclusion by searching PubMed and Google Scholar (last accessed 15 June 2020). Retrospective review of literature. Analysis of epidemiological data concerning obesity prevalence and COVID-19 incidence, particularly in Italy and the USA. Results: Data from several retrospective studies of prevalence showed that patients with hypertension, type 2 diabetes, and obesity may have more severe COVID-19, intensive care unit admission, and higher mortality rates, but it is not definitively clear if this is an independent association. In general, the prevalence of obesity in patients with COVID-19 seems to bethe same as that of the general population throughout the world; however, obesity seems to be associated with more severe disease and mortality in younger (< 60 years) patients. Similar effects seem to occur in patients with diabetes and/or hypertension but at older ages (> 60 years). In strict connection, it has been proposed that the use of drugs inhibiting angiotensin-converting enzyme 2 (ACE-2) or dipeptidyl dipeptidase 4 (DPP-4) might influence viral activity and disease severity since ACE-2 and DPP-4 receptors mediate SARS-CoV- 2 entry into the host cells; however, no evidence exists to date that shows that this may be the case. Conclusion: Overall, diabetes, hypertension, and obesity seem to negatively affect the clinical course and disease outcome in patients with COVID-19. However, these data need further confirmation by studies with more accurate data registration.
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
Buscemi, S., Corleo, D., Randazzo, C. (2022). Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity. In A. Asea, P. Kaur (a cura di), Coronavirus Therapeutics, Advances in Experimental Medicine and Biology (pp. 115-129). Springer Nature [10.1007/978-3-030-85113-2_7].
File in questo prodotto:
File Dimensione Formato  
Buscemi_COVID_Adv Exp Med Biol 2021.pdf

Solo gestori archvio

Descrizione: articolo principale
Tipologia: Versione Editoriale
Dimensione 609.98 kB
Formato Adobe PDF
609.98 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Buscemi publishing agreement.pdf

Solo gestori archvio

Descrizione: publishing agreement
Tipologia: Contratto con l'editore (ATTENZIONE: NON TRASFERIRE A SITO DOCENTE)
Dimensione 4.21 MB
Formato Adobe PDF
4.21 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/534630
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 49
social impact